Heart Failure in Hispanics  by Vivo, Rey P. et al.
B
m
g
g
P
i
r
t
1
h
t
a
e
r
p
c
c
p
a
s
i
c
F
C
U
2
Journal of the American College of Cardiology Vol. 53, No. 14, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PSTATE-OF-THE-ART PAPER
Heart Failure in Hispanics
Rey P. Vivo, MD,* Selim R. Krim, MD,* Cihan Cevik, MD,* Ronald M. Witteles, MD†
Lubbock, Texas; and Stanford, California
Although large-scale heart failure (HF) studies in Hispanic Americans are lacking, some compelling data indicate
that they are a particularly vulnerable population and underscore the need for further research. Hispanics com-
prise the largest and fastest-growing ethnic group in the U.S., in whom the impact of this burgeoning public
health problem may be magnified. Current data show that Hispanics with HF are more likely to be younger and
underinsured than non-Hispanic whites. They have higher rates of readmissions but have lower in-hospital and
short-term mortality rates. Epidemiologic studies demonstrate that Hispanics have excessive rates of diabetes,
obesity, dyslipidemia, and metabolic syndrome. Although hypertension and ischemic heart disease are estab-
lished risk factors in this ethnic group, it may be considered that insulin resistance plays a significant role in the
pathogenesis of HF in Hispanics, accounting for their inordinate cardiometabolic risk burden and the growing
evidence of novel metabolic risk factors for HF. Hispanics encounter multiple barriers to health care influenced
by socioeconomic, linguistic, and cultural factors that, in turn, have an adverse impact on disease prognosis.
Recognition of predominant risk factors and health care disparities in this population is crucial to tailoring ap-
propriate management strategies. This review summarizes epidemiologic and clinical data on Hispanics with HF,
details risk factors and health care impediments, and presents an agenda for future investigation. (J Am Coll
Cardiol 2009;53:1167–75) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.037E
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My midcentury, minorities are projected to become the
ajority in the U.S. Playing a central role in this demo-
raphic shift are Hispanic Americans who lead all ethnic
roups in the U.S. in number and rate of population growth.
resently, 45.5 million Hispanics live in the U.S., compris-
ng 15% of the total population. Spurred by higher birth
ates and immigration, this number is expected to nearly
riple to over 130 million by 2050, when it is projected that
of 3 U.S. residents will be Hispanic (1). As the public
ealth burden of heart failure (HF) continues to increase in
he general population with its health care-related cost
mounting to nearly $30 billion (2), its consequences are
xpected to be magnified among Hispanics for 3 key
easons. Foremost, the remarkable growth in the Hispanic
opulation is expected to present a challenge to the health
are system. Second, Hispanics have a disproportionate
ardiometabolic risk burden (3), making them an important
opulation to elucidate the association between novel met-
bolic risk factors and HF outcomes. Finally, they are
ignificantly and unfavorably affected by health care dispar-
ties shaped by multiple socioeconomic, contextual, and
ultural factors (4,5).
rom the *Department of Internal Medicine, Texas Tech University Health Sciences
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niversity School of Medicine, Stanford, California.p
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etween 2000 and 2006, the Hispanic population grew
lmost 4 times faster (24.3%) than the total U.S. population
6.1%). Approximately 1 of every 2 persons added to the
ational population between 2005 and 2006 was Hispanic,
hereby accounting for nearly one-half of the population
rowth during that period. The majority of Hispanics in the
.S. are of Mexican origin (64%); Puerto Ricans (9%),
ubans (3.4%), and Dominicans (2.8%) constitute other
ajor national groups. Although the largest number of
ispanics resides in California, Texas, Florida, New York,
nd Illinois, the highest Hispanic growth rate has been
eported in the Southeast, particularly in the states of
rkansas, Georgia, South Carolina, Tennessee, and North
arolina (Fig. 1). Mexicans comprise nearly one-third of
he population in Texas and California; approximately
ne-half of the nation’s Dominicans live in New York City,
nd about one-half of the nation’s Cubans reside in Miami-
ade County, Florida. More than 90% of Hispanics reside
n metropolitan regions—a trend strongly driven by migra-
ion from rural farm jobs to urban city occupations that
egan in the 1950s (1).
ace, ethnicity, “Hispanic” clarified. Current federal
tandards describe 5 racial categories: 1) white; 2) black or
frican American; 3) American Indian or Alaska native;
) Asian; and 5) native Hawaiian or other Pacific islander.
eanwhile, ethnic categories are defined as either “His-anic or Latino” or “not Hispanic or Latino” (6).
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Heart Failure in Hispanics April 7, 2009:1167–75It must be emphasized that
Hispanics make up the only eth-
nic group defined not by geo-
graphic origin but rather by com-
mon language (7). “Hispanic” in
health literature broadly refers
to a heterogeneous group of
populations ancestrally linked to
pain and the Spanish-speaking nations of the Caribbean
nd Central and South America (1,3,8). Subcategorizing
he population according to national origin provides a more
recise albeit imperfect classification that may inadequately
xplain variables that impact health outcomes (e.g., accul-
uration) (8). National origin will be cited in this review
ccording to specificity of available data.
emographic and clinical features of HF patients. Per-
inent literature on HF in Hispanics remains scarce due to
heir under-representation in HF trials; this results in
imited data primarily restricted to retrospective subgroup
nalyses. This was confounded by dichotomous (i.e., white
nd black) race/ethnicity coding in older medical databases,
s illustrated by the 1994 expansion of Medicare data to
nclude Hispanics and other minorities (9).
American Heart Association 2008 statistics revealed that
he prevalence of HF was lowest in the Mexican-American
ubgroup, followed by non-Hispanic whites and African
mericans (3). The annual prevalence rates for men were
Abbreviations
and Acronyms
CAD  coronary artery
disease
HF  heart failure
LV  left ventricle
Figure 1 Percent Change in Population by State 2000 to 2006
Geographic differences in population growth of Hispanics in the U.S. Reprinted, wi.1% in Mexican Americans, 2.8% in non-Hispanic whites,
nd 2.7% in African Americans. For women in the same
opulations, the prevalence rates were 1.9%, 2.1%, and
.3%, respectively (Table 1). A study of elderly patients in
lorida, on the other hand, revealed that the prevalence of
elf-reported HF was highest in Hispanic Cubans compared
ith non-Hispanic whites and African Americans; more-
ver, Hispanic Cuban women had the greatest HF preva-
ence rate on sex-adjusted analysis (10). A recent report
rom MESA (Multi-Ethnic Study of Atherosclerosis) doc-
mented that the incidence rate of HF was greater in
frican Americans (4.6 per 1,000 person-years) and His-
anics (3.5) than in non-Hispanic whites (2.4) (11).
frican-American and Hispanic subjects had higher inci-
ent HF with no interim myocardial infarction than non-
ispanic whites did, whereas a greater increase in HF risk
as noted among Hispanics and non-Hispanic whites for
ny given increase in left ventricular (LV) mass index.
Retrospective and observational studies have largely
ocumented that compared with non-Hispanic whites,
ispanics with HF are more likely to be younger (12–14),
nderinsured (12), and to have higher rates of diabetes,
yslipidemia, and kidney disease (12–15). In addition,
ispanics have a relatively higher prevalence of abnormal
V ejection fraction (13,14,16)— usually implying worse
rognosis in HF. An observational analysis from the
DHERE (Acute Decompensated Heart Failure Regis-
anic or Latino
ission, from the U.S. Census Bureau (1).Hisp
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April 7, 2009:1167–75 Heart Failure in Hispanicsry) registry reported that age and rates of renal insuffi-
iency and ischemic cardiomyopathy of Hispanics were
ntermediate between non-Hispanic whites and African
mericans (15).
isk Factors for HF
ispanics are uniformly affected by excessive rates of dia-
etes, overweight and obesity, atherogenic dyslipidemia,
etabolic syndrome, and poorly controlled hypertension (3)
Table 2). The conglomeration of these conditions, includ-
ng related pathophysiologic components that are emerging
s novel risk factors for HF (17,18), is expected to amplify
he risk of this ethnic group for HF.
iabetes. Hispanics are nearly twice as likely to have diabetes
s age-matched non-Hispanic whites (19). Moreover, the
ncrease in diabetes prevalence from 2005 to 2050 is expected
o be highest among Hispanics (20). The high prevalence of
iabetes in this ethnic population has been attributed to higher
ates of obesity (21), highly atherogenic diet consumption (22),
nd genetic susceptibility (23,24). Diabetes-related microvas-
ular complications and mortality are higher in Hispanics than
n non-Hispanic whites (25,26). In addition, diabetic Mexican
mericans less frequently self-monitor their blood glucose and
ave poorer glycemic control than non-Hispanic whites (27).
lthough data have shown that low socioeconomic and edu-
emographic and Clinical Characteristics of Hispanics and Other R
Table 1 Demographic and Clinical Characteristics of Hispanics
Author (Ref. #) Year N (HA) Comparison Groups
Rosamond et al. (3) 2008 5.3 million NHW, AA ● In
● In
Demirovic et al. (10) 2001 2,759 (990) NHW, AA ● S
● S
● P
Bahrami et al. (11) 2008 6,814 (1,492) NHW, AA, CA ● H
i
● I
a
Alexander et al. (12) 1999 90,316 (9,835) NHW, AA, Asians ● H
[
● M
● H
Minutello et al. (13) 2006 76,928 (5,543) NHW, AA ● H
A
● H

Yeo et al. (14) 2007 21,272 (2,561) NHW, AA, Asians ● H
(
● H
● H
(
Jimenez et al. (15) 2004 61,778 (1,662) NHW, AA ● H
● H
● H
Aronow et al. (16) 2001 2,805 (323) NHW, AA ● I
a
● I
a
A African Americans; CA Chinese Americans; CABG coronary artery bypass graft; HA Hisp
VH  left ventricular hypertrophy; LVMI  left ventricular mass index; MI  myocardial infarctionational status, poor medical care access, and inability to speak gnglish do not predict worse glycemic control in Hispanics
27–29), a recent study reported that modifiable self-
anagement behaviors, particularly higher diabetes-specific
motional distress, contribute to uncontrolled hyperglycemia in
his population (30).
Poorly controlled diabetes predicts a higher risk of HF. The
KPDS (United Kingdom Prospective Diabetes Study)
ocumented that every 1% incremental rise in glycated hemo-
lobin increased the risk for nonfatal HF by 16% (31). There
s growing recognition of a “diabetic cardiomyopathy” that
ccounts for the increased risk of developing HF among
iabetics in the absence of coronary artery disease (CAD),
ypertension, or other known structural heart disease (32).
ata from MESA indicating ethnic differences in diabetes-
ssociated LV abnormalities, wherein increased LV mass and
all thickness were completely attributable to subclinical ath-
rosclerosis and hypertension in non-Hispanic whites but not
n Hispanics, suggest a greater contribution from diabetes in
he latter group (33).
besity. More Mexican-American men are overweight than
heir non-Hispanic white and African-American counterparts
3). They also have a higher proportion of abdominal fat than
omen (34). Among women, a higher percentage of Mexican
mericans are overweight and obese than non-Hispanic
hites. Hispanic adults (47.6%) are less likely than African
mericans (51.3%) and non-Hispanic whites (66.1%) to en-
/Ethnic Groups With HF
Other Racial/Ethnic Groups With HF
Findings Relevant to HA
Mexican Americans had lower HF prevalence (2.1%) than NHW (2.8%) and AA (2.7%).
en, Mexican Americans had lower prevalence (1.9%) than NHW (2.1%) and AA (3.3%).
orted HF prevalence rates in elderly highest in Hispanic Cubans (6.7%).
cific prevalence highest in Hispanic Cuban women (8.2%).
age of prior MI lower than in NHW and AA.
ence rates in HA (3.5/1,000 person-years) lower than in AA (4.6) and higher than
(2.4) and CA (1.0).
ed LVMI had the greatest impact on incident HF among HA and NHW; interim
I had the least effect in AA and HA.
ents with HF (54.9% women) were younger than all groups except AA (mean age
: 65.1, HA: 68.7, Asians: 71.9, NHW: 75).
A and Asians were uninsured or had lower Medicare coverage.
all groups in diabetes and renal failure.
ents undergoing PCI (38.8% women) were younger than NHW (mean age [yrs]:
2, HA: 61.5, NHW: 64.8).
e likely to be diabetic and to have HF, acute MI or unstable angina, and LVEF
than either group (HA: 34.1%, NHW: 31.4%, AA: 31.3%).
ents undergoing CABG surgery (31% women) younger than all groups except AA
age [yrs]: AA: 63.17, HA: 64.02, Asians: 65.6, NHW: 66.91).
AA more likely than NHW and Asians to be in HF.
lower mean LVEF (47.12%) than AA (47.71%), NHW (48.73%), and Asians
), and HA had highest rate of diabetes.
ents more often male.
and 15% more likely than AA and NHW, respectively, to have diabetes.
and 1% more likely than AA and NHW, respectively, to have higher cholesterol.
men, the prevalence of LVH/abnormal LVEF (50%) was higher in AA (54%/32%)
(51%/30%) than NHW (36%/28%).
women, the prevalence of LVH/reduced LVEF was also higher in AA (56%/24%)
(53%/25%) than NHW (38%/21%).
ericans; HF heart failure; LAE left atrial enlargement; LVEF left ventricular ejection fraction;
 non-Hispanic whites; PCI  percutaneous coronary intervention.acial
and
men,
wom
elf-rep
ex-spe
ercent
F incid
n NHW
ncreas
cute M
A pati
yrs]: AA
ore H
A led
A pati
A: 61.
A mor
50%
A pati
mean
A and
A had
48.64%
A pati
A 10%
A 11%
n older
nd HA
n older
nd HAage in leisure-time physical activity (3).
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Heart Failure in Hispanics April 7, 2009:1167–75The risk of HF progressively increases 5% in men and 7%
n women for every point increase in body mass index
ithout any apparent threshold (35). Mechanistic, patho-
ogic, and animal studies provide evidence for an “obesity
ardiomyopathy” (likely related to “diabetic cardiomyopa-
hy” or “insulin-resistant cardiomyopathy”) (36–39). Exten-
ive data have shown, however, that a higher body mass
ndex predicts paradoxically better survival after the onset of
F in patients with stable disease and among those with
arying levels of functional impairment (40–44). Proposed
xplanations for the obesity paradox include earlier detec-
ion (due to more symptoms for the same degree of LV
ysfunction), a protective effect from lipoprotein-mediated
own-regulation of cytokines (40,41), and a greater meta-
olic reserve to surmount the catabolic and inflammatory
tresses of cardiac cachexia (42,45).
ypertension. Although Mexican Americans are nearly as
ikely to have hypertension as non-Hispanic whites (3), their
evel of blood pressure control is poorer (46). In addition,
nly 35% of hypertensive Mexican Americans receive treat-
ent and an even lower 14% achieved control compared
ith 24% in non-Hispanic whites (47).
By itself, hypertension more than triples the risk of HF
48). The prevalence of hypertension is increased in patients
ith diabetes, and hypertensive diabetics have worse LV
unction than normotensive diabetics (49). In addition,
ypertension frequently coexists with obesity and is a
ecognized component of metabolic syndrome.
yslipidemia. In contrast to non-Hispanic whites, His-
anics have higher triglyceride and lower high-density
ummary of Cardiometabolic Risk Factors in Hispanics and Their A
Table 2 Summary of Cardiometabolic Risk Factors in Hispanics
Risk Factor Data on HA, Relative to NHW and AA (Ref.
Diabetes ● Age-adjusted prevalence twice that in NHW (9.8% vs. 5%
● Glycemic control poorer than NHW: proportion of Mexica
(40.8%) with HbA1C 8% higher than NHW (35.7%) (27
Overweight/obesity ● Prevalence of overweight: higher in Mexican-American m
than NHW (71%) and AA (67%) men; higher in Mexican-A
women (73%) than NHW (57.6%) (3)
● Prevalence of obesity: slightly lower in Mexican-American
than NHW (30.2%) and AA (30.8); higher in Mexican-Am
(57.6%) than NHW (30.7%) (3)
Hypertension ● BP control poorer than NHW: proportion with systolic BP
and/or diastolic BP 95 mm Hg higher in Mexican Ame
NHW (46)
● Awareness of hypertension lowest: Mexican Americans (
(70%), AA (74%) (47)
● Treatment with medications lowest: Mexican Americans
(54%), AA (57%) (47)
Dyslipidemia ● High prevalence of atherogenic dyslipidemia: high triglyc
HDL, elevated small dense LDL particles (50,51)
● LDL size significantly lower in Mexican Americans (255.8
NHW (257.9 Å) (51)
Metabolic
syndrome
● Age-adjusted prevalence higher in Mexican Americans (3
NHW (23.8%) and AA (21.6%) (62)
● Genetic linkage described (63,64)
MI  body mass index; BP  blood pressure; CAD  coronary artery disease; HbA1C  glycate
bbreviations as in Table 1.ipoprotein levels (50); Mexican Americans, in particular, iave more elevated small, dense low-density lipoprotein
articles (51), a pattern with a high prevalence in type 2
iabetics (52).
Although dyslipidemia is a predisposing risk factor for
F (53), a number of studies have documented that, after
he onset of HF, there is an inverse association between
otal cholesterol levels and survival among HF patients
54 –56). While this paradoxical association has been
xplained by the anti-inflammatory effects of cholesterol
57), some investigators propose that lower cholesterol
evels—like lower body mass index in cardiac cachexia—
ay merely reflect the severity of HF (58). Cholesterol
eduction with statin use has been shown to decrease
ncident HF in patients with CAD (59). However, 2
ecently completed randomized, placebo-controlled trials
emonstrated that statin therapy did not confer significant
urvival benefit among patients with ischemic or nonisch-
mic HF and those with either reduced or preserved systolic
V function (60,61).
etabolic syndrome and insulin resistance. Mexican
mericans lead all race/ethnic groups in the age-adjusted
revalence of metabolic syndrome (62). A genetic linkage of
ncreased susceptibility to insulin resistance in the Hispanic
opulation has been reported (63,64).
A distinct insulin-resistant cardiomyopathy, supported by
asic science and clinical evidence, was recently postulated
s a dominant cause of nonischemic HF (65). Furthermore,
uman data have demonstrated that metabolic syndrome is
significant predictor of LV dysfunction and incident HF,
ndependent of blood pressure or intervening myocardial
iation With HF
Their Association With HF
Known Associations With HF
ricans
● Independent risk factor for HF
● Poorer glucose control, higher HF risk
● Diabetic cardiomyopathy
.6%)
an
(29.1%)
women
● Independent risk factor for HF
● Higher BMI, higher HF risk
● Obesity cardiomyopathy
● Obesity paradox: higher BMI, better outcomes
mm Hg
than
NHW
, NHW
● Established risk factor for HF
, low
n in
● Increased apolipoprotein B/A-I ratio independent risk factor for HF
● Cholesterol paradox: lower cholesterol levels, higher mortality
● Statin therapy does not confer survival benefit
than in ● Marked insulin resistance in HF patients
● Insulin resistance predicts altered LV geometry and HF incidence
● Metabolic syndrome independent risk factor for HF
● Insulin-resistant cardiomyopathy
oglobin; HDL  high-density lipoprotein; LDL  low-density lipoprotein; LV  left ventricle; otherssoc
and
#)
) (19)
n Ame
)
en (74
meric
men
erican
160
ricans
54%),
(35%)
erides
Å) tha
1.9%)nfarction (66,67).
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April 7, 2009:1167–75 Heart Failure in Hispanicsther Etiologic Conditions of HF
few traditional and less conventional etiologies of HF are
elevant to Hispanic patients.
AD. In contrast to non-Hispanic whites, some data have
hown that Hispanics have a lower atherosclerotic burden
emonstrated by lower prevalence of obstructive CAD, abnor-
al coronary artery calcium score (68), and common carotid
rtery intima-media thickening (69), even after adjusting for
isk factor differences. Further evidence demonstrating an
nexpectedly lower cardiovascular mortality among Hispanics
espite their high cardiometabolic risk have indicated a “His-
anic paradox” (70–73). Contrary to this concept, more recent
tudies that prospectively ascertained vital status information
ave reported similar or higher all-cause and cardiovascular
eath rates in Mexican Americans than in non-Hispanic
hites (74,75). Among women with acute coronary syndrome,
ispanics and non-Hispanic whites have been found to have
imilar in-hospital risk-adjusted mortality (76).
heumatic heart disease. The national incidence of rheu-
atic fever and rheumatic heart disease has declined sub-
tantially but remains high in a few populations including
ispanics, particularly Mexican Americans (3,77). One
tudy reported that the age-adjusted mortality rates for
heumatic heart disease in New Mexico over a 25-year
eriod were higher in Hispanics than in non-Hispanic
hites (77). Another study of patients presenting for mitral
alve surgery revealed that Hispanics were younger and had
igher prevalence of rheumatic disease and HF than non-
ispanic adults (78). These observations have been attrib-
ted to poorer economic status and access to public health
ervices in this group (77,78).
hagas’ disease. First described in Brazil and etiologically
inked to the parasite Trypanosoma cruzi by Carlos Chagas
79), American trypanosomiasis or Chagas’ disease is an
mportant cause of HF in endemic regions including Mex-
co and Central and South America, where approximately
6 to 18 million people are infected (80). Although previ-
usly considered rare in the U.S., an estimated 50,000 to
350,000 Hispanic immigrants may have chronic, asymp-
omatic T. cruzi infection (80,81) with a 20% likelihood of
rogression to chronic cardiomyopathy in this population
82). Chagas’ disease in the U.S. is principally driven by
mmigration, yet disease transmission can also occur via
lood transfusion or organ transplant, or congenitally in
regnant women (80). Apart from HF, Chagas’ heart
isease may present as angina, fatal arrhythmias, or sudden
eath (83). Misdiagnosis of idiopathic dilated cardiomyop-
thy or CAD is common due to poor disease recognition in
oth patients and medical professionals, especially in non-
ndemic areas (81).
iagnostic and Treatment Patterns
study of Medicare beneficiaries examining ethnic dispar-
ties in quality of HF care reported that compared with don-Hispanic whites and African Americans, Hispanics
ere least likely to have an assessment of LV ejection
raction and to be discharged on angiotensin-converting
nzyme inhibitor treatment (84). The OPTIMIZE-HF
Organized Program to Initiate Lifesaving Treatment in
ospitalized Patients with Heart Failure) study showed
hat Hispanic ethnicity was an independent predictor for
ondelivery of complete discharge instructions, even among
ospitals serving the highest proportion of this population
85). Data from the GWTG-HF (Get With the Guide-
ines–Heart Failure) program demonstrated that the per-
entages of Hispanic patients receiving 2 HF performance
easures (discharge instructions and angiotensin-converting
nzyme inhibitor or angiotensin-receptor blocker therapy)
ere intermediate between African Americans and non-
ispanic whites. For 2 GWTG-HF quality indicators
aldosterone antagonist therapy for LV systolic dysfunction
nd lipid lowering therapy), the percentages of Hispanics
eceiving them were higher than either subgroup (86).
utcomes
xisting data indicate that despite their higher rates of
ospitalization (87) and readmission (12) than non-
ispanic whites, Hispanics with HF have lower in-hospital
87) and short-term mortality rates (12) (Table 3), even
fter adjustment for age and sex. Furthermore, Hispanic
atients were most likely to be discharged home and least
ikely to be discharged to a skilled nursing facility (87).
The ADHERE registry analysis documented that in-
ospital mortality and length of stay of Hispanics were
ntermediate between non-Hispanic whites and African
mericans (15). A multicenter study demonstrated more
ignificant improvement in health-related quality of life over
ime in Hispanics with HF than in other ethnic groups after
ontrolling for demographic, clinical, and treatment differ-
nces (88).
arriers to Health Care
lthough eliminating racial/ethnic health disparities is a
ajor goal of the Healthy People 2010 national public
ealth agenda (89), there are insufficient strategies that
ddress numerous health care barriers in Hispanics (4,90).
cross populations, Hispanics have the poorest health
nsurance access: over one-third of them have no medical
nsurance (91). In addition, they are most likely to have no
sual place of care (92) and to have the most difficulty
aying for medical care, irrespective of insurance status (93).
mong different Hispanic subgroups, Mexican Americans
re least likely to be insured and to use preventive health
ervices (92). Cuban Americans more frequently have in-
urance coverage as a result of employment benefit or higher
ncomes, whereas Puerto Ricans are more likely to be
overed by Medicaid (5,92).
Acculturation, a measure of integration of a group into a
ominant culture (92), has been documented as a direct
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Heart Failure in Hispanics April 7, 2009:1167–75orrelate of cardiovascular disease screening adherence
mong Mexican Americans (94). A study reported that
horter U.S. residence predicts fewer ambulatory or emer-
ency care visits and lower likelihood to have any prescrip-
ion medications (5). In the U.S., Hispanics have the lowest
evel of education (93), an important correlate of health risk.
nother significant variable of acculturation and health care
mpediment for many Hispanics is the language barrier.
bout 8 million Hispanics in the U.S. do not speak English
uently (95). Monolingual Spanish speakers have a higher
revalence of cardiovascular risk factors and poorer recog-
ition of coronary symptoms (96). In turn, exclusively
nglish-speaking physicians engage Hispanic patients less
ffectively in their medical care than do bilingual physicians
97). Additionally, providers may contribute to disparities
hrough clinical uncertainty and stereotyping of health
ehaviors related to minority patients (98).
Improving the cultural competency of providers requires
wareness of health beliefs inherent to Hispanic culture.
alues such as trust (confianza) and personalized care
personalismo), essential in the physician-patient relation-
ifferences in HF Outcomes Across Racial/Ethnic Groups
Table 3 Differences in HF Outcomes Across Racial/Ethnic Grou
Author (Ref. #)
Follow-Up
(Months) Outcome Measured
Brown et al. (87) NA HF admission, in-hospital mortality,
discharge disposition
Alexander et al. (12) 12, after index
hospitalization
Readmission or death
Jimenez et al. (15) NA In-hospital mortality, LOS
Riegel et al. (88) 3 and 6, from
enrollment
HRQOL
RQOL  health-related quality of life; LOS  intensive care unit length of stay; MLHFQ  Minne
bbreviations as in Table 1.
ey Considerations for Future Studies
Table 4 Key Considerations for Future Studies
Representation in patient registries, research studies, and clinical trials
● Sufficient representation of Hispanics, reflective of their proportion in the popula
● Given the heterogeneity of this ethnic population, subgroup analyses between na
● Accounting for data indicating the willingness of Hispanics to be involved in rese
their participation.
Risk factor modification
● The precise influence of cardiometabolic risk on HF presentation and outcomes
● Although the cardiometabolic risk burden of Hispanics is significant, it is importa
environmental, and genetic risk factors modulate the pathogenesis of HF in this
Evaluation and reduction of health care disparities
● The degree to which barriers to both outpatient and in-hospital HF care, as well a
Hispanic population.
● Further efforts should determine other potential sources of health care disparitiebbreviations as in Table 1.hip, may drive Hispanics to consult with family, friends, or
raditional healers before seeking an empathic provider.
elays in medical treatment may also be ascribed to customs
ncluding fatalism and submission to the will of God (99).
ata showing that Hispanics were more likely to consider
ypertension as an expected and untreatable consequence of
ging indicate that specific health attitudes may contribute
o underuse of preventive services (100). Other cultural
actors including unique disease perception, spirituality,
tronger social support, and coping mechanisms, however,
ave been shown to positively impact health-related quality
f life in Hispanic HF patients (88).
An important barrier to expanding the knowledge on
ispanics is limited research representation. A review of
ultiethnic clinical trials conducted in the U.S. between
995 and 1999 noted that Hispanic subjects constituted
nly 3% of participants, which was far lower than their
epresentation in the national population (101). Among
atients enrolled in 83 trials from the Veterans Affairs
ooperative Studies Program (1975 to 2000), 76%, 20%,
nd 4% were non-Hispanic whites, African Americans, and
Comparison
Groups Findings Relevant to HA
NHW, AA, Asians ● Age-adjusted prevalence (per 1,000 enrollees) of HF
hospitalization higher for AA (32) and HA (25.6) than
NHW (21.2) and Asians (11.3).
● Age-standardized prevalence of in-hospital mortality lower
for AA (3.6%), HA (4.5%), and Asians (4.5%) than NHW
(5.1%).
● HA most likely to be discharged home rather than to SNF.
NHW, AA, Asians ● Percentage of patients rehospitalized for HF higher in AA
(24.5%) and HA (23.4%) than in NHW (19.9%) and Asians
(19.6%).
● Percentage of patients who died within 12 months of HF
admission were equally lower among HA (25.4%) and AA
(25.4%) than among Asians (32.3%) and NHW (34.2%).
NHW, AA ● Intermediate between NHW and AA.
NHW, AA ● More significant improvement in HA measured by higher
MLHFQ total scores.
ving with Heart Failure Questionnaire; NA  not applicable; SNF  skilled nursing facility; other
fundamental to meaningful racial/ethnic comparisons.
ased populations should be considered thoughtfully.
nvestigators should use culturally sensitive methods to recruit them and sustain
anics should be examined thoroughly.
nvestigate how much traditional (i.e., ischemic and hypertensive heart disease),
.
edical and nonpharmacologic treatment, should be assessed methodically in the
appropriate interventions to reduce them.pstion, is
tion-b
arch, i
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April 7, 2009:1167–75 Heart Failure in Hispanicsispanics, respectively. Trials involving an invasive inter-
ention enrolled even fewer ethnic minorities (102). Data
howing that Hispanics are as willing as non-Hispanic
hites to participate in health research suggest that their
nder-representation in research studies is less likely a result
f reluctance to enroll but rather inadequate access provided
y investigators/funding organizations (103). Other factors
imiting minority participation in research include poor
nformation dissemination, geographic inaccessibility of
tudy sites, language/cultural barriers (e.g., Spanish transla-
ion of recruitment, consent, protocol materials), insufficient
eimbursement of travel cost, and legal apprehensions of
ndocumented immigrants (103–105).
onclusions and Future Directions
hereas the validity of studying diseases on the basis of
ace/ethnicity has been occasionally fraught with skepticism,
vailable data suggest that Hispanics with HF manifest
emographic and clinical features, as well as health care
hallenges, distinct from other populations. Compelling
vidence indicate that Hispanic ethnicity is marked by a
isproportionate cardiometabolic risk burden, largely due to
xceedingly high rates of insulin resistance. Therefore, we
ypothesize that the central concept of insulin resistance—
ompounded by inflammation and neuroendocrine overactivity—
ay be a predominant etiologic factor for cardiomyopathy in
ispanics. We propose the following agenda for further investi-
ation (Table 4):
Adequate representation of Hispanics in HF registries and
trials is paramount to expand the database and to construct
significant data comparisons across other racial/ethnic pop-
ulations. Subgroup analyses between Hispanic nationalities
should reflect the ethnic diversity of the population.
It is imperative to evaluate the magnitude and mechanisms
by which health care barriers affect HF presentation and
outcomes in Hispanics. The paradox of higher hospitaliza-
tion rates and lower mortality may be partly driven by
poorer access to quality outpatient care, highlighting the
importance of accounting for health care access variables
when examining clinical end points (12).
Cardiometabolic risk biomarkers, subclinical disease param-
eters, and clinical end points should be examined thor-
oughly. Risk factor control (e.g., glycated hemoglobin,
medication adherence) should also be assessed. Prospective
studies with sufficiently long follow-up should help determine
whether the reverse epidemiology shown by the obesity and
cholesterol paradoxes are based on true association, survival
bias, or reverse causation (45).
Our hypothesis intuitively invites the possibility of specific
therapeutic targets and strategies for populations with
strong cardiometabolic risk. The efficacy of newer pharma-
cologic options for cardiometabolic risk reduction, such as
inhibitors of the poly(adenosine diphosphate-ribose) poly-
merase (32) and the cannabinoid-1 receptor (106), should
be investigated.cknowledgments
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